Attendee search 

Silence Therapeutics is a leading RNAi company, developing highly innovative medicines with life-saving potential for patients with serious and rare diseases, based upon its proprietary technology platform in GalNAc conjugated siRNA.

The Company is in a strong position to maximise the potential of its IP and technology through collaborations and the advancement of internal programmes toward the clinic. Silence’s lead candidate SLN124 will move into clinical development in the coming year.

Chugai Pharma Europe Ltd. is seeking for in-licensing and partnering opportunities for its European key territories in UK, Germany and France. We strive to build our business model on existing partnerships in oncology/hematology and rheumatology as well as to grow as a organization with strong commercialization expertise, broad market access and pricing knowledge and valuable experience in medical advocacy and KOL Management.

We look forward to meeting you in Montreux,

Ryo ishimura and Florian Streckert 

Alliance Pharma is an internation specialty pharma busienss with a buy and build business model and asset light operations. We have a balanced portoflio of growth focussed international star brands and a cash-generative Bedrock requiring minimal promotional support. We have 20 years of operation, 35 deals experience and have been on the London stock exchange junior market (AIM) since 2003 (LSE: APH). 2017 results: £100m+ sales, 27% EBITDA, £20m+ FCF, dividend paying Our star brands are: Kelo-cote – fastest drying, silicone gel anti-scar treatment  MacuShield – exact match to the protective pigments found on the macula Vamousse – most technologically advanced treatment for head lice Nizoral – medicated anti-dandruff shampoo acquired from J&J in June 2018      

Imperial Innovations is the Technology Transfer office for Imperial College London and selected NHS Trusts around London. Imperial College London is ranked in the world's top ten (QS Rankings 2018) and is the second-most innovative university in Europe (Reuters 2018).

We work closely with academic inventors to bring their research projects to market. We work with a diverse range of technologies, from diagnostics to surgical tools, therapeutics to digital healthcare solutions. We are experts in identifying, evaluating and backing technologies that meet industrial market need.

-We assess inventions, considering commercial potential, the state of the market and development requirements

-We protect intellectual property through patents and other appropriate forms of intellectual property protection

-We provide advice on establishing proof of concept, using our commercial experience to inform inventors about what businesses want to see

-We may provide development funding or support inventors in their applications for funding from other sources

-We advise on IP and commercial strategy

-We manage the licensing process (including negotiations and post-deal administration)

-Our Venture Support Unit establishes new businesses, finds mentors and management and provides access to preferred suppliers

-Above all we are flexible in our support – capable of executing novel deals and providing unique support where required.